The quarter's standout achievement was the company's ability to scale profitability whilst expanding its top line, with net sales climbing 24.23% year-on-year to ₹7,047.51 crores. Operating margins excluding other income expanded dramatically to 34.27%, marking the highest quarterly margin in recent history. However, the stock's muted response reflects concerns about sustainability and the company's historical margin volatility.
The pharmaceutical major's performance in Q2 FY26 represents a significant inflection point in its multi-year turnaround journey. After struggling with regulatory challenges and margin pressures in previous years, Lupin appears to have found its operational rhythm, delivering its highest-ever quarterly profit alongside robust revenue expansion. The company's ability to achieve 21.74% PAT margin—up from 15.64% in the same quarter last year—demonstrates improved operational efficiency and favourable product mix dynamics.
| Quarter | Revenue (₹ Cr) | QoQ Growth | Net Profit (₹ Cr) | QoQ Growth | OPM (Excl OI) | PAT Margin |
|---|---|---|---|---|---|---|
| Sep'25 | 7,047.51 | +12.43% | 1,477.92 | +21.24% | 34.27% | 21.74% |
| Jun'25 | 6,268.34 | +10.61% | 1,219.03 | +57.80% | 28.02% | 19.82% |
| Mar'25 | 5,667.13 | -1.74% | 772.52 | -9.66% | 23.75% | 14.07% |
| Dec'24 | 5,767.71 | +1.67% | 855.16 | +0.30% | 24.13% | 15.29% |
| Sep'24 | 5,672.73 | +1.29% | 852.63 | +6.40% | 24.38% | 15.64% |
| Jun'24 | 5,600.33 | +12.89% | 801.31 | +122.94% | 22.50% | 14.61% |
| Mar'24 | 4,960.79 | — | 359.43 | — | 20.36% | 7.52% |
Financial Performance: Stellar Profit Growth Driven by Margin Expansion
Lupin's Q2 FY26 financial performance showcased exceptional operational leverage, with the company converting strong revenue growth into disproportionately higher profit expansion. Net sales in Q2 FY26 reached ₹7,047.51 crores, marking a sequential improvement of 12.43% over Q1 FY26 and a robust 24.23% year-on-year growth. This acceleration in top-line momentum suggests improving demand dynamics across the company's key markets, particularly in the United States and India.
The standout feature of the quarter was the dramatic margin expansion across all profitability metrics. Operating profit before depreciation, interest, and tax (excluding other income) surged to ₹2,341.33 crores, translating to an operating margin of 34.27%—up 628 basis points sequentially from 28.02% in Q1 FY26 and a substantial 989 basis points higher than the 24.38% recorded in Q2 FY24. This represents the highest quarterly operating margin in the company's recent history, signalling improved product mix, operational efficiencies, and favourable pricing dynamics.
Net profit after tax climbed to ₹1,484.83 crores on a standalone basis and ₹1,477.92 crores on a consolidated basis, reflecting year-on-year growth of 73.34%. The PAT margin expanded to 21.74%, up from 19.82% in the previous quarter and 15.64% in the corresponding quarter last year. This margin improvement was achieved despite a sequential increase in interest costs to ₹107.59 crores from ₹91.76 crores, reflecting higher working capital requirements and debt levels.
The tax rate for Q2 FY26 stood at 26.02%, significantly higher than the 13.71% recorded in Q1 FY26 but in line with normalised tax rates. The lower tax rate in Q1 FY26 appears to have been an aberration, likely reflecting one-time adjustments or deferred tax benefits. The normalisation of the tax rate in Q2 FY26 provides a more sustainable basis for projecting future profitability.
Operational Excellence: Margin Leadership Amidst Scale Expansion
Lupin's operational performance in Q2 FY26 demonstrates the company's ability to achieve scale whilst maintaining—and even expanding—profitability metrics. The operating profit to net sales ratio (excluding other income) of 34.27% positions Lupin amongst the most efficient pharmaceutical manufacturers in India, reflecting a combination of favourable product mix, pricing power in key therapeutic areas, and operational improvements.
Employee costs in Q2 FY26 rose to ₹1,105.56 crores from ₹1,083.00 crores in Q1 FY26, representing a sequential increase of 2.08%. As a percentage of sales, employee costs declined to 15.69% from 17.27% in the previous quarter, indicating improved labour productivity and operating leverage. This trend is particularly encouraging given the pharmaceutical industry's reliance on skilled scientific and commercial talent.
The company's return on equity (ROE) for FY25 stood at 19.08%, a significant improvement from the average ROE of 8.95% over recent years. This higher ROE reflects both improved profitability and efficient capital deployment. However, it's worth noting that the latest ROE of 19.08% represents a substantial improvement from historical levels, suggesting that the company has successfully turned around its capital efficiency after a period of underperformance.
Operational Highlights
Record Operating Margin: Q2 FY26 operating margin of 34.27% represents the highest in company history, driven by favourable product mix and operational efficiencies.
Operating Leverage: Operating profit to interest coverage ratio reached 21.76 times in Q2 FY26, the highest level recorded, indicating strong debt servicing capability.
Improved Capital Efficiency: Latest ROE of 19.08% demonstrates significant improvement in capital productivity, though investors should monitor sustainability given historical volatility.
The balance sheet as of March 2025 shows shareholder funds of ₹17,203.50 crores, up from ₹14,290.29 crores in the previous year, reflecting retained earnings accumulation. Long-term debt increased to ₹1,766.23 crores from nearly zero in the previous year, indicating strategic borrowing for growth initiatives or acquisitions. The debt-to-EBITDA ratio of 3.10 times (on average) remains within manageable limits, though the recent increase in leverage warrants monitoring.
Product Mix Dynamics: The Margin Expansion Story
The exceptional margin expansion witnessed in Q2 FY26 appears to be driven primarily by favourable changes in Lupin's product portfolio mix. Whilst the company does not provide detailed segment-wise breakdowns in quarterly filings, the magnitude of margin improvement—from 28.02% to 34.27% in just one quarter—suggests a significant shift towards higher-margin products, likely in the specialty and complex generics categories.
Lupin's strategic focus on respiratory, cardiovascular, anti-diabetic, and anti-infective therapies has historically provided stable revenue streams with improving margins as the company gains scale and regulatory approvals. The company's investments in research and development, which averaged around 8% of sales historically, appear to be bearing fruit through new product launches and market share gains in existing products.
However, the pharmaceutical industry is characterised by inherent margin volatility due to factors such as pricing pressures in the US generics market, regulatory compliance costs, and product mix fluctuations. Lupin's historical margin trajectory—ranging from 20.36% in March 2024 to 34.27% in September 2025—highlights this volatility. Investors should exercise caution in extrapolating the current elevated margins without visibility into the sustainability of the underlying product mix.
Margin Volatility: A Key Monitoring Point
Lupin's operating margins have demonstrated significant quarter-to-quarter volatility, ranging from 20.36% to 34.27% over the past seven quarters. Whilst the current 34.27% margin is impressive, investors should monitor whether this level can be sustained or if it represents a peak driven by one-time favourable factors. The company's five-year average ROCE of 8.85% compared to the latest 22.16% suggests historical challenges in maintaining elevated returns.
Industry Context: Navigating the Global Pharmaceutical Landscape
The global pharmaceutical industry in 2025 continues to face a complex operating environment characterised by pricing pressures in developed markets, regulatory scrutiny, and evolving competitive dynamics. For Indian pharmaceutical companies like Lupin, the US market—which typically accounts for a significant portion of revenues—remains challenging due to continued generic pricing erosion and consolidation amongst buyers.
However, several countervailing trends favour well-positioned players like Lupin. The growing emphasis on complex generics and specialty pharmaceuticals offers higher margin opportunities for companies with strong R&D capabilities and regulatory track records. Additionally, the Indian domestic market continues to grow at healthy mid-to-high single-digit rates, providing a stable revenue base less susceptible to pricing pressures.
Lupin's five-year sales growth of 9.24% and EBIT growth of 31.55% demonstrate the company's ability to navigate this challenging environment and capture market share. The substantially higher EBIT growth compared to sales growth indicates improving operational efficiency and margin expansion over the medium term, though as noted earlier, this trajectory has been uneven.
| Metric | FY25 | FY24 | FY23 | FY22 | 5Y CAGR |
|---|---|---|---|---|---|
| Net Sales (₹ Cr) | 22,707.00 | 20,010.00 | 16,641.00 | 16,405.00 | 9.24% |
| Operating Profit (₹ Cr) | 5,277.00 | 3,800.00 | 1,720.00 | 218.00 | 31.55% |
| Operating Margin (%) | 23.20% | 19.00% | 10.30% | 1.30% | — |
| PAT (₹ Cr) | 3,306.00 | 1,935.00 | 447.00 | -1,509.00 | — |
| PAT Margin (%) | 14.60% | 9.70% | 2.70% | -9.20% | — |
Peer Comparison: Valuation Discount Despite Strong Performance
Lupin's valuation metrics present an interesting contrast to its operational performance. At a price-to-earnings ratio of 24.15 times trailing twelve-month earnings, Lupin trades at a significant discount to the pharmaceutical sector average P/E of 36 times. This valuation gap persists despite Lupin's strong recent performance and improving margin profile.
The company's price-to-book value ratio of 5.19 times is broadly in line with peers such as Zydus Lifesciences (3.93 times) and Mankind Pharma (6.67 times) but significantly higher than Dr Reddy's Laboratories (0.28 times) and Cipla (0.37 times). However, these latter comparisons may be distorted by accounting differences or asset revaluations.
| Company | P/E (TTM) | P/BV | Div Yield | Debt/Equity |
|---|---|---|---|---|
| Lupin | 24.15 | 5.19 | 0.61% | 0.07 |
| Dr Reddy's Labs | 17.42 | 0.28 | 0.66% | -0.03 |
| Cipla | 22.27 | 0.37 | — | -0.25 |
| Zydus Lifesciences | 19.89 | 3.93 | 1.17% | -0.19 |
| Torrent Pharma | 59.79 | 15.91 | 0.73% | 0.33 |
| Mankind Pharma | 50.40 | 6.67 | 0.04% | 0.44 |
Lupin's relatively modest P/E multiple of 24.15 times appears attractive when considered alongside its recent earnings momentum and margin expansion. The company's PEG ratio of 0.38 (calculated using five-year EBIT growth of 31.55%) suggests the stock may be undervalued relative to its growth trajectory. However, investors should consider that pharmaceutical earnings can be volatile, and historical growth rates may not persist.
The company's dividend yield of 0.61% is modest compared to peers like Zydus Lifesciences (1.17%) but reflects a conservative payout ratio of 16.70%, leaving ample room for reinvestment in growth initiatives or future dividend increases. The low debt-to-equity ratio of 0.07 provides financial flexibility, though the recent increase in long-term debt to ₹1,766.23 crores warrants monitoring.
Valuation Analysis: Attractive Entry Point with Caveats
Lupin's current valuation of ₹1,956.05 per share, representing a market capitalisation of ₹90,402 crores, appears attractive on multiple metrics. The stock trades at a P/E ratio of 24.15 times, which is below the pharmaceutical sector average of 36 times and represents a reasonable premium to the company's historical average given the recent improvement in profitability and margins.
The company's enterprise value to EBITDA multiple of 15.77 times and EV to EBIT of 20.02 times are broadly in line with pharmaceutical industry norms for a company of Lupin's size and growth profile. The EV to sales ratio of 3.88 times reflects the market's recognition of Lupin's improved margin profile, though this multiple could face pressure if margins revert towards historical averages.
Lupin's proprietary Mojo Score of 57 out of 100 places the stock in "HOLD" territory, reflecting a balanced assessment of the company's strengths (improving financials, attractive valuation) against concerns (technical weakness, recent underperformance). The valuation grade of "Very Attractive" suggests that at current prices, the stock offers reasonable value for patient investors willing to look through near-term volatility.
Based on a normalised earnings multiple of 25-27 times (reflecting the company's improved margin profile and growth trajectory), Lupin's fair value can be estimated at ₹2,100-2,250 per share, implying upside potential of 7-15% from current levels. However, this valuation assumes that the company can sustain operating margins in the 28-30% range, which is above historical averages but below the exceptional 34.27% achieved in Q2 FY26.
Stock Performance: Recent Weakness Despite Strong Fundamentals
Lupin's stock performance has been disappointing in recent months despite the company's strong operational results. The stock is down 9.65% over the past year, underperforming both the Sensex (up 3.65%) and the pharmaceuticals sector (down 3.36%). Year-to-date, the stock has declined 16.80%, significantly underperforming the Sensex's 6.62% gain.
This disconnect between operational performance and stock price movement reflects several factors. First, the market may be sceptical about the sustainability of Q2 FY26's elevated margins, given the company's historical volatility. Second, technical factors have weighed on the stock, with the current "Mildly Bearish" trend classification indicating negative momentum. Third, broader market rotation away from mid-cap pharmaceutical stocks may have contributed to selling pressure.
| Period | Lupin Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | +0.56% | -1.30% | +1.86% |
| 1 Month | +0.93% | +1.86% | -0.93% |
| 3 Months | +5.64% | +3.44% | +2.20% |
| 6 Months | -4.41% | +3.31% | -7.72% |
| YTD | -16.80% | +6.62% | -23.42% |
| 1 Year | -9.65% | +3.65% | -13.30% |
| 2 Years | +63.01% | +28.25% | +34.76% |
| 3 Years | +175.23% | +36.69% | +138.54% |
The longer-term picture is more encouraging. Over three years, Lupin has delivered returns of 175.23%, significantly outperforming the Sensex's 36.69% gain with alpha of 138.54 percentage points. This longer-term outperformance reflects the company's successful turnaround from the challenges faced in FY22, when it reported a loss of ₹1,509 crores.
From a technical perspective, the stock trades below all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), indicating weak near-term momentum. The stock is currently 18.61% below its 52-week high of ₹2,403.45 but 10.26% above its 52-week low of ₹1,774.00. Technical indicators present mixed signals, with MACD showing "Mildly Bullish" on the weekly timeframe but "Mildly Bearish" on the monthly timeframe.
Investment Thesis: Quality Improving but Execution Consistency Needed
Lupin's investment case rests on three key pillars: improving operational performance, attractive valuation, and a strong balance sheet providing financial flexibility. The company's Q2 FY26 results demonstrate significant progress on the operational front, with record margins and strong profit growth. The valuation, at 24.15 times trailing earnings, appears reasonable for a company with improving fundamentals and growth potential.
However, several factors temper enthusiasm. The company's quality grade of "Average" reflects concerns about the sustainability of recent performance improvements. The average ROCE of 8.85% over recent years, whilst improving to 22.16% in the latest period, suggests historical challenges in maintaining elevated returns on capital. The significant quarter-to-quarter margin volatility—from 20.36% to 34.27% over seven quarters—raises questions about the predictability of earnings.
The technical picture remains challenging, with the stock in a "Mildly Bearish" trend and trading below all major moving averages. Whilst fundamentals have improved, the market appears to be adopting a wait-and-see approach, possibly seeking confirmation that the Q2 FY26 margin performance can be sustained over multiple quarters before re-rating the stock.
Key Strengths & Risk Factors
KEY STRENGTHS
- Record Profitability: Q2 FY26 operating margin of 34.27% represents the highest in company history, demonstrating operational excellence and favourable product mix
- Strong Revenue Momentum: 24.23% year-on-year revenue growth indicates robust demand across key markets and successful product launches
- Attractive Valuation: P/E of 24.15x represents significant discount to pharmaceutical sector average of 36x, offering value for patient investors
- Improved Capital Efficiency: Latest ROE of 19.08% demonstrates substantial improvement from historical average of 8.95%, indicating better capital deployment
- Strong Balance Sheet: Low debt-to-equity ratio of 0.07 provides financial flexibility for growth investments or strategic acquisitions
- Diversified Portfolio: Presence across multiple therapeutic areas and geographies reduces concentration risk and provides multiple growth levers
- Institutional Confidence: 47.05% institutional holdings reflect confidence from sophisticated investors in the company's long-term prospects
KEY CONCERNS
- Margin Volatility: Operating margins have ranged from 20.36% to 34.27% over seven quarters, raising questions about sustainability of current elevated levels
- Historical Inconsistency: Average ROCE of 8.85% over recent years, despite latest improvement to 22.16%, suggests challenges in maintaining elevated returns consistently
- Technical Weakness: Stock in "Mildly Bearish" trend, trading below all major moving averages, indicating negative near-term momentum
- Recent Underperformance: Down 9.65% over past year, underperforming Sensex by 13.30 percentage points despite strong operational results
- Rising Interest Burden: Interest costs increased to ₹107.59 crores in Q2 FY26 from ₹91.76 crores in Q1 FY26, reflecting higher debt levels
- US Market Challenges: Continued pricing pressure in US generics market poses ongoing headwind to revenue growth and margin sustainability
- Quality Rating: "Average" quality grade reflects concerns about consistency of financial performance and execution track record
Outlook: What to Watch in Coming Quarters
POSITIVE CATALYSTS
- ✓ Margin Sustainability: Maintaining operating margins above 30% for 2-3 consecutive quarters would validate the structural improvement thesis
- ✓ New Product Approvals: Additional ANDA approvals or specialty product launches could drive incremental revenue and margin expansion
- ✓ Market Share Gains: Evidence of market share expansion in key therapeutic areas would support sustained revenue growth
- ✓ Technical Reversal: Stock breaking above 200-day moving average of ₹1,988.52 would signal improving momentum and potential trend reversal
RED FLAGS TO MONITOR
- ⚠ Margin Compression: Any sequential decline in operating margins below 28% would raise concerns about sustainability of recent improvement
- ⚠ Revenue Deceleration: Slowing revenue growth below 10% year-on-year would indicate weakening demand or competitive pressures
- ⚠ Rising Debt Levels: Further increases in debt without corresponding EBITDA growth could pressure credit metrics and financial flexibility
- ⚠ Technical Breakdown: Stock falling below 52-week low of ₹1,774.00 would signal serious technical deterioration requiring reassessment
The Verdict: Improving Fundamentals Meet Market Scepticism
Score: 57/100
For Fresh Investors: Lupin presents a compelling turnaround story with attractive valuation, but the lack of consistency in margin performance and weak technical setup warrant a cautious approach. Consider building positions gradually on further weakness towards ₹1,850-1,900 levels, with a 12-18 month investment horizon to allow the company to demonstrate sustained operational improvement.
For Existing Holders: Continue holding positions, as the company's improving fundamentals and attractive valuation provide a reasonable margin of safety. However, maintain discipline with regards to position sizing, and consider booking partial profits if the stock approaches ₹2,200-2,300 levels without corresponding improvement in margin sustainability visibility.
Fair Value Estimate: ₹2,150 (10% upside potential), contingent on the company demonstrating sustained operating margins of 28-30% over the next 2-3 quarters and maintaining revenue growth above 15% year-on-year.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance does not guarantee future results, and pharmaceutical stocks carry inherent risks related to regulatory approvals, pricing pressures, and competitive dynamics.
